Innovation is transformative. It’s why we ride in a Mustang instead of on a mustang. Centuries of knowledge now fit in the palm of our hand. Products move from reliable to revolutionary. Yet ideas ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Abstract: For any given target trajectory, asymptotic tracking error convergence can be achieved as the number of iterations tends to infinity by applying existing ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

America is the global leader in health care innovation. We lead in medical research and in rapidly developing treatments for emerging health care priorities. That leadership isn’t free. But it isn’t ...

Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company, visit the Nasdaq MarketSite in Times Square on January 22 to ring the Nasdaq Opening Bell and celebrate the “Era of ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...